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(+)-Neplanocin B ((+)-5), the unnatural isomer of a minor component of the neplanocin family 
of antibiotics was enantioselectively synthesized starting from D-ribono-1,4-lactone. This 
synthetic strategy employed (+)-9-[(1R, 2R, 5S)-5-Benzyloxy-3-(benzyloxy)methyl-2-hydroxy-
cyclopent-3-en-1-yl]-6-chloropurine (compound 7) as an advanced synthetic intermediate. 
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The term carbanucleoside refers to a nucleoside analogue in which a methylene group has 
replaced the oxygen atom of the furanose ring.1−5 Surprisingly, these analogues are recognized 
by the same enzymes that recognize normal nucleosides exhibiting, in the same way, a broad 
range of pharmacological properties mainly as antiviral and antitumor agents.6,7 The neplanocin 
family is an important class of natural carbocyclic nucleosides isolated from Ampullariella 
regularis as fermentation products.7 Of the neplanocins, that include at least five components, 
such as neplanocin C ((−)-1), neplanocin A ((−)-2), neplanocin D ((−)-3), neplanocin F ((−)-4), 
and neplanocin B ((−)-5), only 1 and 2 have received much attention (Figure 1). 
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(-)-1, neplanocin C (-)-2, neplanocin A (-)-3, neplanocin D (-)-5, neplanocin B(-)-4, neplanocin F
 
 
Figure 1. Chemical structures of the neplanocin family of naturally occurring carbanucleosides. 
 
The sugar moiety of nucleosides in solution exists in a dynamic equilibrium between the 
Northern-type geometry and the facing Southern-type geometry according to the concept of the 
pseudorotational cycle.8 However, only one of these conformers is found in the crystalline 
structure, and only the Northern or Southern conformer is exclusively responsible for molecular 
recognition as well, since only one form is present in the drug-enzyme complex. However, as the 
conformation in solution may be unlike that found in the solid state, any attempt to correlate 
sugar conformation with biological action would be flawed unless the crystal and the solution 
conformation are the same. A cyclopropane or an epoxy ring can confer such rigidity to the sugar 
ring, in which the equilibrium N  S is not observed indicating that the solution conformation 
is practically the same to that found in the crystal.
⇔
9 Neplanocin C (1),10 is a good prototype of a 
conformationally locked nucleoside analogue, which is built on an oxabicyclic[3.1.0]-hexane 
system that allows this compound to exhibit the typical Northern-type (N) conformation, 
specifically in the 2E geometry. This conformation is very close to a pure 3T2 (P = 0º) geometry 
as determined by the P value of the pseudorotational cycle (P value = 338.03º and νmax = 21.89º) 
from the solved X ray structure.10f The chemical structure of neplanocin C was taken as lead 
drug for the design of a substantial number of conformationally restricted carbocyclic 
nucleosides of biological importance.11 The enantioselective synthesis of neplanocin C has been 
recently achieved employing D-ribonolactone as chiral starting material.12 The crucial point in 
the preparation of neplanocin C was the extraordinary stability of the epoxy group under 
methanolic ammonia at high temperature, which are the conditions required to convert a 6-
chloropurine derivative into an adenosine derivative.12 This fact has been used both to synthesize 
the corresponding 2'-deoxyneplanocin C analogues13 and to prepare simple and closely related 
carbanucleosides built in [3.1.0]oxabicyclo systems.14 A very interesting example constitutes a 
normal nucleoside built in a 2-oxabicyclic[3.1.0]hexane system.15 Taking nucleoside 6 as an 
example, this compound seems to be a closely related analogue of neplanocin B. Molecular 
modeling studies on 6 indicate that the optimized energy conformer presents a geometry close to 
a 0T1 conformation (P = 107.2°) with a νmax = 17.2°. The presence of a fused-three membered 
ring in this 2-oxabicyclo[3.1.0]hexane scaffold locks the sugar moiety in a C1'-exo type 
conformer according to the pseudorotational cycle. 
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The lack of pharmacological activity data of neplanocin B encouraged us to develop an entry 
to access to carbanucleoside 5. Therefore, in this work we describe the first synthesis of the 
unnatural isomer of neplanocin B, which could be useful for the synthesis of analogues and 
closely related derivatives. 
 
 
Results and Discussion 
 
The synthesis of (+)-neplanocin B was successfully carried out employing compound (+)-9-[(1R, 
2R, 5S)-5-benzyloxy-3-(benzyloxy)methyl-2-hydroxy-cyclopent-3-en-1-yl]-6-chloropurine (7), 
which in turn, was prepared from D-ribose in twelve steps.16 The adenosine precursor 7 was also 
employed as an advanced synthetic intermediate in the enantioselective synthesis of (+)-
neplanocin F.16 Therefore, compound 7 was transformed into epoxy derivative 8 by treatment 
with m-chloroperbenzoic acid in 75% yield. The course of the epoxidation reaction was directed 
by the hydroxyl group and occurred with high stereoselectivity to afford a single diastereomer 
according to the Henbest rule.17 Formation of the diastereomeric β epoxide was not observed. 
Treatment of 8 with methanolic ammonia gave the desired carbocyclic analogue of adenosine 9. 
In addition, no N-oxide by-products were observed. Once again, the epoxy group was resistant to 
these strong basic conditions. Benzyl ethers cleavage with hydrogen in the presence of palladium 
on charcoal afforded the title compound, (+)–neplanocin B ((+)–5) in 70% yield for the first 
time. Compound numbering for all carbocyclic rings was kept for clarity in the NMR signal 
assignment, as illustrated for (+)-5 in Scheme 1. 
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Scheme 1. Reagents and conditions: (a) m-CPBA, CH2Cl2, 0 ºC → rt, 48 h, 75%; (b) 
methanol/NH3, 70 ºC, 5 h, 60%; (c) H2, Pd/C, methanol/HCOOH, 3 atm, 70%. 
 
In order to uncover the lowest energy conformer of neplanocin B ((+)–5), a conformational 
search was carried out. The initial conformations were generated by random variation of the 
dihedral angles using the conformational search protocol and the MM+ method as implemented 
in HyperchemTM Release 7.52. A set of low-energy conformations were then minimized using 
ab-initio methods at the restricted Hartree-Fock (RHF) level of theory with the 3-21G basis set.18 
Finally, DFT optimizations using the B3LYP functional and the 6-31G* basis set19 were 
performed on selected local minima. Frequency calculations were used to confirm the nature of 
the stationary points. Ab initio and DFT calculations were carried out using GAUSSIAN 98.20 
The global minimum structure thus located has a south-type conformation possessing a 1E 
geometry with P = 128.18º and νmax = 34.43º (Figure 3). As was previously observed for 
nucleoside 6, the oxirane moiety of 5 appears to lock the conformation of the five-membered 
ring to a C1'-exo puckering mode. The greater stability of the global minimum relative to other 
1E conformers that have been found can be attributed to the presence of two intramolecular 
hydrogen bonds, as evidenced by the computed O-H and N-H distances depicted in Figure 3. Our 
calculations are supported by the relatively large experimental values obtained for J1'2' of 5 (7.2-





front view top view
 
 
Figure 3. Lowest energy conformer of neplanocin B. 
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In conclusion, we present the first total enantioselective synthesis of (+)–neplanocin B taking 
advantage of the availability of synthetic intermediate 7, which was employed for the 
enantioselective preparation of another member of neplanocin family, (+)–neplanocin F (4). 
Efforts aim at exploiting new synthetic methods to prepare neplanocin analogues are currently 





General Procedures. The glassware used in air and/or moisture sensitive reactions was flame-
dried and carried out under a dry argon atmosphere. Unless otherwise noted, chemicals were 
commercially available and used without further purification. 
Nuclear magnetic resonance spectra were recorded using a Bruker AM-500 MHz 
spectrometers. Chemical shifts are reported in parts per million (δ) relative to tetramethylsilane. 
The 1H-NMR spectra are referenced with respect to the residual CHCl3 proton of the solvent 
CDCl3 at 7.26 ppm. Coupling constants are reported in Hertz. 13C-NMR spectra were fully 
decoupled and are referenced to the middle peak of the solvent CDCl3 at 77.0 ppm. Splitting 
patterns are designated as s, singlet; d, doublet; t, triplet; q, quartet. 
Melting points were determined using a Fisher-Johns apparatus and are uncorrected. 
Positive ion fast atom bombardment mass spectra (FABMS) were obtained on a VG ZAB 
BEqQ spectrometer at an accelerating voltage of 8 kV and a resolution of 500. Thioglycerol was 
used as the sample matrix, and ionization was effected by a beam of cesium atoms. Accurate 
mass analysis for the final products was conducted at a resolution of 3000 (10% valley) in the 
molecular ion region using charge-exchanged xenon atoms and glycerol as a matrix. The 
glycerol peaks at m/z 277 (Gly3H+), 369 (Gly4H+) and 461 (Gly5H+) were used as reference ions 
and the VG-7070-EHF mass spectrometer was voltage scanned under control of Maspec-II data 
system. Standard data system was used to assign and calculate masses for the reference and 
sample ions, respectively. 
Column chromatography was performed with E. Merck silica gel (Kieselgel 60, 230-400 
mesh). Analytical thin layer chromatography was performed employing 0.2 mm coated 
commercial silica gel plates (E. Merck, DC-Aluminum sheets, Kieselgel 60 F254) and was 
visualized by 254 nm UV or by immersion into an ethanolic solution of 5% H2SO4. 
 
(1S, 2S, 3R, 4R, 5R)-4-Benzyloxy-1-benzyloxymethyl-3-(6-chloropurin-9-yl)-6-oxabicyclo 
[3.1.0]hexan-2-ol (8). To a solution of compound 7 (120 mg, 0.259 mmol) in methylene chloride 
(5 mL) was added dropwise a solution of 80% m–chloroperbenzoic acid (179 mg, 0.51 mmol) in 
methylene chloride (3 mL) at 0 ºC. The reaction mixture was stirred at room temperature for 48 
h. The solvent was evaporated and the residue was purified by column chromatography using a 
mixture of hexane–EtOAc (1:1) as the eluent to afford 91 mg (75% yield) of pure epoxide 8 as a 
colorless oil: Rf 0.70 (hexane-EtOAc, 4:1); 1H NMR (500.13 MHz, CDCl3) δ 3.75 (d, J = 1.1 Hz, 
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1 H, H-4'), 3.84 (d, J = 11.4 Hz, 1 H, CHaHOBn), 4.04 (d, J = 11.4 Hz, 1 H, CHHbOBn), 4.36 (t, 
J = 7.6 Hz, 1 H, 1 H, H-1'), 4.35 (d, J = 12.3 Hz, 1 H, PhCHaHO), 4.62 (m, 3 H, PhCHHbO, 
PhCH2), 4.70 (dd, J = 8.0, 1.1 Hz, 1 H, H-5'), 5.03 (d, J = 7.5 Hz, 1 H, H-2'), 6.92-7.05 (m, 5 H, 
aromatic protons), 7.29-7.39 (m, 5 H, aromatic protons), 8.03 (s, 1 H, H-8), 8.45 (s, 1 H, H-2); 
13C NMR (125.77 MHz, CDCl3) δ 57.54 (C-1'), 63.33 (C-3'), 65.17 (C-4'), 67.32 (CH2O), 70.85 
(C-2'), 71.80 (CH2Ph), 73.87 (CH2Ph), 75.38 (C-5'), 127,64 (Ph), 127.86 (Ph), 128.05 (Ph), 
128.13 (Ph), 128.53 (Ph), 136.67 (Ph), 137.34 (Ph), 146.04 (C-8), 152.17 (C-2). 
(1S, 2S, 3R, 4R, 5R)-3-(6-Aminopurin-9-yl)-4-benzyloxy-1-benzyloxymethyl-6-oxabiciclo 
[3.1.0]hexan-2-ol (9). Compound 8 (100 mg, 0.209 mmol) was treated with methanolic 
ammonia (5 mL, saturated at –78 ºC) and heated in sealed tube at 70 ºC for 5 h. The mixture was 
cooled to room temperature and the solvent was evaporated. The residue was purified by column 
chromatography (silica gel) using EtOAc as the eluent to afford 58 mg (60% yield) of pure 9 as a 
white solid: Rf 0.12 (hexane-EtOAc, 1:9); mp 172 ºC; [α]24D + 31.8 (c 0.3, methanol); 1H NMR 
(500.13 MHz, CDCl3) δ 3.70 (s, 1 H, H-4'), 3.80 (d, J = 11.2 Hz, 1 H, CHaHOBn), 4.05 (d, J = 
11.4 Hz, 1 H, CHHbOBn), 4.29 (t, J = 7.5 Hz, 1 H, H-1'), 4.49 (d, J = 12.1 Hz, 1 H, PhCHaHO), 
4.60 (d, J = 7.7 Hz, 1 H, H-5'), 4.62 (m, 2 H, PhCH2), 4.65 (d, J = 12.1 Hz, 1 H, PhCHHbO), 
4.93 (d, J = 7.3 Hz, 1 H, H-2'), 5.83 (s, 2 H, NH2), 7.08-7.12 (m, 2 H, aromatic protons), 7.14-
7.18 (m, 3 H, aromatic protons), 7.28-7.36 (m, 5 H, aromatic protons), 7.64 (s, 1 H, H-8), 8.03 (s, 
1 H, H-2); 13C NMR (125.77 MHz, CDCl3) δ 57.57 (C-1'), 63.35 (C-3'), 64.19 (C-4'), 67.15 
(CH2O), 70.94 (C-2'), 71.52 (CH2Ph), 73.83 (CH2Ph), 76.65 (C-5'), 119.97 (C-5), 127,71 (Ph), 
127.95 (Ph), 128.01 (Ph), 128.33 (Ph), 128.53 (Ph), 136.98 (Ph), 137.48 (Ph), 141.19 (C-8), 
149.71 (C-4), 152.05 (C-2), 155.21 (C-6); HRMS (FAB) Calcd for C25H26N5O4 (MH+) 460.1985, 
found 460.1998. 
((+)–Neplanocin B, (1S, 2S, 3R, 4R, 5R)-(+)–3-(6-Aminopurin-9-yl)-1-hydroxymethyl-6-
oxabicyclo[3.1.0]hexane-2,4-diol ((+)–5). A solution of compound 9 (40 mg, 0.087 mmol) in 
methanol (8 mL) and formic acid (0.4 mL) in the presence of 5% palladium black (5 mg) was 
treated with hydrogen at 3 atm. The reaction was stirred at room temperature for 4 h. The 
mixture was filtered off and the solvent was evaporated. The residue was purified by column 
chromatography (silica gel) employing a mixture of CH2Cl2-MeOH (4:1) as eluent to afford 17 
mg (70% yield) of pure (+)–5 as a white solid: mp > 270 ºC (lit.10e mp 269–272 ºC, decomp.); 
[α]24D + 2.1 (c 0.3, DMSO), lit.10e [α]24D –3.5 (c 1.0, DMSO) for the natural isomer; UV (MeOH) 
λmax 260 nm; 1H NMR (500.13 MHz, DMSO-d6) δ 3.51 (s, 1 H, H-4'), 3.52 (dd, J = 11.8, 5.0 Hz, 
1 H, CHaHOH), 3.88 (dd, J = 12.4, 6.5 Hz, 1 H, CHbHOH), 4.06 (t, J = 7.9 Hz, 1 H, H-1'), 4.63 
(t, J = 7.2 Hz, 1 H, H-5'), 4.70 (dist t, J = 7.2 Hz, 1 H, H-2'), 4.85 (t, J = 5.8 Hz, 1 H, OH), 5.43 
(d, J = 6.4 Hz, 1 H, OH), 5.47 (d, J = 5.7 Hz, 1 H, OH), 7.15 (s, 2 H, NH2), 8.07 (s, 1 H, H-8), 
8.10 (s, 1 H, H-2); 13C NMR (125.77 MHz, DMSO-d6) δ 57.59 (C-1'), 59.18 (CH2OH), 64.61 (C-
3'), 64.72 (C-4'), 69.66 (C-2'), 69.69 (C-5'), 119.94 (C-5), 141.76 (C-8), 149.74 (C-4), 151.91 (C-
2), 156.02 (C-6); HRMS (FAB) Calcd for C11H14N5O4 (MH+) 280.1046, found 280.1042. 
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